The Relationship Between Q Angle and Quadriceps Muscle Activation on Dynamic Balance in Women (Quadriceps)

May 20, 2021 updated by: merve yilmaz menek, Istanbul Medipol University Hospital
The quadriceps angle (Q angle) is significant for the lower extremity alignment. Anatomical alignment of Q angle is related to Quadriceps muscle strength. Women have consistently been found to have larger Q angles than men and are more often affected due to patellofemoral problems. Quadriceps muscle activation and lower extremity alignment affect musculoskeletal health in women.The aim of this study wa s to determine the relationship between Q angle and quadriceps muscle activation on dynamic balance in women.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Objective: To determine the relationship between Q angle and quadriceps muscle activation on dynamic balance in women. Design: Correlational Study. Setting: University. Participants: Forth women will be included in the study. Interventions: Q angle in standing and supine positions, quadriceps muscle activation, static and dynamic balance and functionality were measured. Main Outcome Measurements: Q angle will measured with a tape measure; muscle activation will measured with Surface Electromyography (EMG) static balance will measured with Flamingo Balance Test (FBT); dynamic balance will measured with ProKin 252 Techno Body device; and, functionality will measured with Short Form Musculoskeletal Assessment (SFMA). Before the evaluation of EMG amplitude on dynamic balance position, the Q angle will measured in supine and standing positions. The EMG signals collected by measuring the muscle activation of the Vastus Medialis and Vastus Lateralis during dynamic balance position on the ProKin device will recorded.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey
        • Istanbul Medipol University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

19 years to 25 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • The inclusion criteria were being women, being aged 19-25, and not having musculoskeletal or neurological problems.

Exclusion Criteria:

  • Exclusion criteria were having an operation in the past year, taking medicine related to lower limb problems, persistent pain and discomfort of the lower extremity.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: OTHER
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
EXPERIMENTAL: Experimental group
Before the evaluation of EMG amplitude on dynamic balance position, the Q angle was measured in supine and standing positions. The EMG signals collected by measuring the muscle activation of the Vastus Medialis and Vastus Lateralis during dynamic balance position on the ProKin device were recorded. Q angle evaluations, static and dynamic balance and functional status of all participants were evaluated.
Other: Evaluation of Q angle and Quadriceps muscle activation on dynamic balance position
Evaluation of Q angle, Quadriceps muscle activation, static and dynamic balance and functionality of all individuals was done.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Q angle evaluation
Time Frame: 5 minutes
The Q angle was measured with a standard universal goniometer. It was measured by drawing a line from the Anterior Superior Iliac Spine to the center of the patella and a second line from the center of the tibial tubercle to the center of the patella.
5 minutes
Electromyographic (EMG) measurements
Time Frame: 15 minutes
EMG biofeedback is a device that detects neuromuscular contractions and provides feedback signals to the subject. During the ProKin 252 Techno Body balance system, Vastus Medialis and Vastus Lateralis muscles activity levels were recorded at 1000-Hz sample data-regulating Surface EMG device and analyzed using the Biometrics Datalog (UK) system.
15 minutes
Dynamic Balance Evaluation
Time Frame: 15 minutes
Dynamic balance was evaluated by ProKin 252 Techno Body balance device. The participants were taken to the balance platform on the right foot with their eyes open, after determining the reference interval and setting the test time as 30 seconds.They were instructed to stay balanced on the platform
15 minutes

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Static Balance Evaluation
Time Frame: 5 minutes
Static balance was assessed with Flamingo Balance Test (FBT) in open and closed eyes conditions.The subjects stood on the beam which was 50 cm long, 5 cm in height and 3 cm wide. Then the instructor started the stopwatch and the subjects tried to stand in this position for one minute. When the time was over, the subjects' attempts after they fell were counted and this score was recorded
5 minutes
Functionality Assessment
Time Frame: 5 minutes
The functional status of subjects was evaluated with the Short Musculoskeletal Function Assessment Questionnaire (SMFA).
5 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul Medipol University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 15, 2019

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 13, 2021

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 15, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 13, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 20, 2021

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 21, 2021

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 21, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 20, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2021

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • merveyilmaz

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

I will publish my manuscript about this study, so researchers can access my individual participant's daha with this way.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings